《盈警響號》健倍苗苗(02161.HK)料中期盈利按年減少超過50%
健倍苗苗(02161.HK)發盈警,預期截至2021年9月30日止中期盈利將按年減少超過50%,對比2020年同期錄盈利約2,165萬元。
公司解釋,主要由於疫情導致國內及若干海外市場的消費者需求疲弱,相關地區旅遊限制持續,對集團若干產品的銷售及售價造成負面影響,加上期內香港特區政府未再發放疫情影響紓困補貼。
健倍苗苗表示,期內健康保健品分部推出多項新產品,跨境電子商務平台亦取得良好進展,展望未來將繼續優化其資源以實現增長策略,同時本著務實態度力求通過成本控制措施減省成本。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.